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Abstract 
 
The human papillomavirus (HPV) is the most commonly spread sexually transmitted infection in 
the United States. Although the HPV vaccine protects against transmission of the most common 
strains of HPV that cause genital warts and numerous urogenital cancers, uptake in the United 
States remains suboptimal. Failure to vaccinate leaves individuals vulnerable to the virus and 
subsequent complications of transmission. The evidence demonstrates that provider 
recommendation alone increases rates of vaccine uptake. The literature does not suggest a 
specific method for provider recommendation delivery; however, best practice alerts (BPAs) 
were correlated with increased vaccination rates. These findings have directed a proposed project 
that includes an electronic health record (EHR) change prompting internal medicine, family 
practice and women’s health providers to educate and recommend the HPV vaccine at a 
Federally Qualified Health Center (FQHC) in the Southwest United States. The project 
demonstrates that after the implementation of a practice change of a HPV BPA in the EHR, HPV 
vaccination rates increased. Practice settings pre and post were similar, making the increase 
clinically significant. The strengths of this project include an increase in HPV vaccination rates, 
a sustainable intervention, and an intervention that can easily be replicated into other health 
maintenance tasks. There were some limitations including the BPA alert only catching the HPV 
9 vaccine series and the BPA did not always capturing historical data. Despite these technical 
barriers the HPV BPA delivered an increase in the HPV vaccine to protect more individuals from 
the HPV virus, increased provider adherence to national guidelines, and provides a platform for 
BPAs to be utilized for other vaccines. 
 Keywords: human papillomavirus, vaccine, provider recommendation, uptake, 
electronic health record 
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The Impact of a Human Papillomavirus Vaccine Best Practice Alert 
The human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) among women in the United States (CDC, 2016d). Some strains of the virus can develop 
into genital warts, and others can lead to the development of cervical and other urogenital 
cancers (CDC, 2015). Fortunately, a vaccination exists to prevent the transmission of HPV and 
protect sexually active individuals from developing complications from the infection. Although 
strongly recommended by many national organizations including the Center for Disease Control 
and Preventions (CDC), the Advisory Committee for Immunization Practices (ACIP), and the 
American Congress of Obstetricians and Gynecologists (ACOG), HPV vaccination rates 
continue to be sub-optimal (ACOG, 2015; CDC 2016c; CDC, 2015; Hofstetter & Rosenthal, 
2016).  
Problem Statement 
 HPV infections cause greater than 17,000 cancers in women every year in the United 
States (CDC, 2015c). In Arizona, 6.3 out of every 100,000 women will develop cervical cancer, 
and 2.4 out of every 100,000 will die from it (CDC, 2016a). HPV strains 16 and 18 are 
responsible for about 80% of cervical cancer incidences, where strains 6 and 11 account for 90% 
of all cases of genital warts (CDC, 2016d). The HPV vaccine protects individuals from these 
four strains, along with five other cancer-causing strains (CDC, 2016d).  The Healthy People 
2020 national initiative notes that only 28.1% of females ages 13-15 have been vaccinated with 
recommended doses, and presents a future goal of 80% or greater compliance rate by 2020 
(Office of Disease Prevention and Health Promotion, 2017). The implementation of regular 
Papanicolaou (Pap) screenings has dropped cervical cancer from the most common cancer in 
females to significantly lower (fourth in the world) (ODPHP, 2017).  In spite of advancements in 
HPV BPA ALERT 
 
4 
screening and the development of the HPV vaccine, in 2013, almost 12,000 women were 
diagnosed with cervical cancer and over 4,000 died from it in the United States (CDC, 2016b).  
 Considering the implications of contracting HPV and the dangers of the cancers it can 
lead to, along with the effectiveness of the HPV vaccination, increasing uptake of the vaccine 
would have a widespread impact on healthcare costs and reduction of disease. Thus, the purpose 
of this project is to explore the impact of a provider best practice alert (BPA) on HPV 
vaccination rates in eligible females ages 18-26. 
Background and Significance 
 The HPV vaccine was approved in 2006 for females ages 9-26 and was later approved for 
males in 2009. In 2016, the CDC released a recommendation that children ages 11-12 only 
require two of the three doses in the series, while those 13 and older still require the three-part 
series (Meites, Kempe, & Markowitz, 2016). In addition, the vaccine originally protected against 
four strains of the virus but in 2015, the ACIP announced their support of the newer 9-valent 
HPV vaccine that protects against five additional strains of HPV (Petrosky et al., 2015).  The 
new vaccine provides more coverage and has been extensively studied for its safety, 
immunogenicity, and efficacy. In regards to safety, few side effects or adverse events have been 
confirmed related to the vaccine, the most common being edema and redness at injection site. 
(Petrosky et al., 2016).  
 In women, HPV can lead to vulvar, cervical, vaginal, oropharyngeal, or anal cancers and 
cervical precancers (Petrosky et al., 2016). The HPV vaccine prevents the transmission of HPV 
thus preventing the development of said cancers. Despite the implications of contracting the 
HPV virus, vaccination rates in women are low across race and ethnic demographics (Bartlett & 
Peterson, 2011).  While initiation of the three-part series is low, rates of completion of the series 
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are even less.  In 2013, less than 40% of females had completed the series (National Vaccine 
Advisory Committee, 2016). It is hypothesized that provider influence is a factor in the 
decreased vaccination uptake rates. 
Lack of provider recommendation is one of the largest barriers to vaccination and the 
likelihood of vaccination increases with provider endorsement (Bartlett & Peterson, 2011). The 
2015 National Vaccine Advisory Committee reported that a third of patients surveyed were not 
offered the HPV vaccine by their provider. In the same survey, a majority of those who declined 
the vaccine reported they did so because they felt they did not have enough information 
regarding the vaccine (National Vaccine Advisory Committee, 2016).  Provider recommendation 
and education have been shown to influence vaccination rates as well as patient behaviors 
(Berenson, Rahman, Hirth, Rupp, & Sarpong, 2015). It has also been shown that as few as 14% 
of providers recommend the HPV vaccine to eligible patients (Berkowitz, Malone, Rodriguez, & 
Saraiya, 2015). The lack of education and endorsement of the HPV vaccine has likely led to 
missed opportunities for eligible patients to receive the HPV vaccination.  
A gap of care exists between vaccination awareness and vaccination rates. Provider 
oversight is a large barrier that contributes to this gap of care. Clinical reminders for providers to 
endorse vaccinations have been shown to improve vaccination rates (Bartlett & Paterson, 2011). 
BPAs integrated into electronic health records (EHRs) provide a reminder to providers to address 
vaccine status. BPAs have been shown to increase numerous vaccination rates including the flu, 
pneumococcal, and the HPV vaccine (Klatt & Hopp, 2012; Ledwich et al., 2009; Ruffin et al., 
2015). Furthermore, provider recommendation in conjunction with practice alerts is an effective 
intervention at increasing uptake rates of the HPV vaccine (Fiks et al., 2013). 
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Evidence strongly supports that provider recommendation increases uptake regardless of 
the educational tools utilized (Bratic, Seyferth, & Bocchini, 2016). Although provider 
recommendation correlates directly with increased uptake, anecdotally patients rarely make 
appointments for vaccines alone. Often a chief complaint pulls focus away from HPV education 
if it is addressed at all. Utilizing each patient appointment as an opportunity to screen for vaccine 
discrepancies, and vaccinate same-day are two interventions that complement provider 
endorsement and increase uptake rates (Gilkey et al., 2016). A BPA integrated into an EHR can 
provide a resource for providers to decrease missed opportunities for HPV vaccination.  
After a thorough literature review, the common theme to increase HPV vaccination rates 
is provider recommendation and BPAs. Providers must utilize every opportunity to educate and 
provide the HPV vaccine at every visit. No one intervention or educational tool was as impactful 
as provider support of and recommendation of the vaccine. As provider recommendation and 
BPA have been proven to increase uptake of many vaccines beyond HPV, it stands to reason that 
if providers were able to consistently recommend the HPV vaccine, that uptake rates would 
increase. 
Internal Evidence 
 One Federally Qualified Health Center (FQHC) also reflects the vaccination uptake 
disparity. This FQHC located in the Southwest United States, like many across the United States 
have low HPV uptake rates. The most common factor contributing to the lack of immunization 
uptake is lack of provider recommendation. This was attributed to many factors including focus 
on a different chief complaint, short appointment times, and the lack of an EHR prompt for HPV 
vaccination status. Providers simply forget to ask and thus miss the opportunity to educate about 
the HPV vaccine. Furthermore, the demographic where HPV vaccinations are typically missed in 
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this FQHC are females, between 18-26 years of age. Fortunately, the knowledge and attitudes of 
these providers about the HPV vaccine were positive, and all providers interviewed agree that 
this is a gap in care. 
Problem Statement and PICOT 
 Although rates of cervical cancer diagnoses and deaths are relatively low in the state of 
Arizona, the HPV vaccine uptake rates continue to be low. Not only does the HPV vaccine 
protect against the most commonly spread STI that can lead to many other diseases, it is a safe, 
quick, and cost-effective intervention that can have a significant impact on the health of women 
(and men). By reducing the spread of HPV, the aforementioned cancers, precancers and warts, 
will be reduced, thus lowering healthcare costs related to caring for these diagnoses. 
 This inquiry has lead to the clinically relevant PICOT question, “In females ages 18-26 at 
a FQHC in the Southwest United States, does an HPV BPA impact rates of HPV vaccination?” 
Search Sources and Process 
In order to provide background to answer this question, the following databases were 
extensively searched: EBSCOhost, ProQuest, and PubMed (See Appendix A). 245 related 
articles were yielded from these database searches. The titles and abstracts were reviewed to 
determine the relevance to this PICOT question and deleted or retained accordingly (see 
Inclusion and Exclusion Criteria below). Ancestry searches were also performed on systematic 
reviews and literature reviews identified in articles from these database searches.  
Inclusion and Exclusion Criteria 
Inclusion criteria encompassed articles related to provider recommendation and BPAs. 
Articles needed to be within the last five years or older if relevant, however the final articles 
were all within that timeframe. Given that the vaccine has only been on the market for 12 years, 
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finding current literature was easily performed. Studies involving parents of eligible adolescents 
or adult women were both acceptable. Studies performed primarily on men were excluded, as 
well as any studies not peer reviewed, studies that did not discuss uptake or the gap in uptake, 
and any study that focused on interventions educating providers instead of on patient-provider 
interaction. All editorials were excluded.  
Due to current nature of this topic, 245 relevant articles were produced with these initial 
searches. These titles and abstracts were reviewed and certain studies not relevant to the PICOT 
question were discarded. About 100 studies were evaluated for relevance, and even fewer were 
critically appraised. Among these studies, multiple ancestry searches were performed on the 
bibliographies of appropriate studies, which yielded some relevant studies. Finally, 12 studies 
were selected from both database searches and ancestry searches. These 12 adequately 
summarize both the current literature on HPV vaccination uptake, and examine provider 
recommendation and BPAs and their role in HPV vaccination uptake.   
Evidence Synthesis 
 The evidence concludes that stagnant HPV rates are a problem and points to provider 
recommendation as a current barrier and solution. The data consistently correlates higher rates of 
vaccination uptake with a provider recommendation. Consistently noted barriers to uptake 
include lack of provider recommendation, lack of adequate education and knowledge on HPV, 
and potential financial concerns related to HPV vaccination. The literature also shows that BPAs 
are associated with an increase in provider awareness of vaccine eligibility. An increase in 
provider awareness increases the likelihood of vaccine recommendation. With consistent 
screening and discussion, providers can not only provide a platform for education, but also 
ultimately improve HPV vaccine uptake rates. Also, with the existence of government-assisted 
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vaccination programs, the provider can educate on available resources to eliminate the financial 
barrier. As provider recommendation and BPAs have been proven to increase uptake of many 
vaccines including HPV, it stands to reason that if providers were able to consistently 
recommend the HPV vaccine, uptake rates would increase. 
Purpose Statement 
 The purpose of this project is to examine the impact of an HPV vaccine BPA within the 
EHR as a clinical reminder on HPV vaccine status for women ages 18-26. This practice change 
will benefit providers and patients at a FHQC in the Southwest United States. 
Contribution of Theory to Utility of the Evidence 
 The Health Promotion Model, created by Nola Pender, is a demonstration of how 
individuals are complex in how they interact with their environment to achieve health (Nursing 
Theory, 2016). The model illustrates that prior behavior and personal factors influence how 
individuals perceive barriers to act, how they perceive their ability to act, influence interpersonal 
and situational perceptions, and how all of those components come together to influence a plan 
of action. The Health Promotion Model relates to the integration of a HPV BPA by ultimately 
influencing behavioral outcomes to increase provider recommendation of the HPV vaccine and 
HPV vaccine uptakes rates (See Appendix B). 
Evidence Based Practice Model to Guide Project Development 
 The Ottawa Model of Research (OMR) lends itself to an implementation of a systematic 
change involving BPAs to prompt provider recommendation. The OMR is an ongoing 
continuum of assessment of barriers and supports to change (which consists of evidence based 
innovation, potential adopters, and practice environment), monitoring of the intervention and 
assessment of its use (which involves implementation strategies and adoption), and evaluation of 
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outcomes (Rycroft-Malone & Bucknall, 2010). It is a continuum in that once evaluation occurs; 
the implementer may go back to the assessment portion, the monitoring portion, or both.  With 
the implementation of a project that changes provider behavior to include HPV endorsement and 
vaccination rates, evaluation of strategies, barriers, practice environment, and monitoring of 
outcomes are important to perform repeatedly and may occur in many different orders. This 
allows for assessment of what is effective and what is not, and provides an environment where 
innovation and improvement are occurring constantly, all for the betterment of patient outcomes 
and increased HPV vaccine uptake. This model provides a step-by-step road map for 
implementation of a provider recommendation change starting with assessment of patient’s 
environment, including their social, cultural, and environmental perceptions about the HPV 
vaccine; assessing potential adopters for this change including key stakeholders; 
implementing/adopting the change, and then assessing how this has impacted uptake rates. 
 This model adequately incorporates not only those who will adopt the change; providers, 
medical assistants, allied health staff, but for the individuals for whom the practice change is 
implemented. By understanding personal barriers to vaccination uptake, providers can create 
interventions and recommendations that are personalized and impactful. 
Project Methods 
Ethics  
Protection of human subjects was achieved though Arizona State University Institutional 
Research Board approval obtained on October 27th, 2017. No recruitment or funding was utilized 
during this project.  
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Setting and Population 
The setting was a system of FQHCs in the Southwest United States encompassing 
women’s health, family practice, and internal medicine practices. Participants include 68 
providers working in these clinics and non-pregnant females ages 18-26.  
Intervention 
The intervention is an EHR change to the existing Clinical Decision Support System 
(CDSS) section of the EHR to alert providers of eligible females that need the HPV vaccine. The 
alert appears red if the patient is due for one of the HPV vaccinations within the series (See 
Appendix C) or appears green if the patient is up-to-date, the vaccine has been documented, or 
ordered by a provider (See Appendix D). This section of the EHR is already being utilized for 
other health promotion activities such as alcohol use screening, Chlamydia screening, smoking 
status, and depression screening. 
Prior to the project, the EHR lacked a BPA for the HPV vaccine and there was no 
uniform method by which providers ascertained vaccine eligibility. After working with the 
information technology department and EHR champions, the BPA was created in the training 
environment of the EHR and went live at this facility in November of 2017. Providers were 
educated on this change at meetings. Any provider that was not in attendance at the meetings 
was education on a one-to-one session with an EHR champion. 
 Collaboration occurred with EHR personnel to implement the HPV BPA and the provider 
EHR champion acted as a liaison between EHR personnel and the investigator. Provider 
champions were called upon to relay information about the intervention to their respective 
departments.  
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Outcome Measures  
Outcome measures include number of patients that received the HPV vaccine and total 
number of patient visits. De-identified reports containing this information were obtained from 
EHR personnel. No tools or instruments were used in this project. Data analysis includes 
descriptive statistics, paired samples T-tests to compare the frequency of vaccination rates by 
clinic, and standardized by total patients seen pre and post- intervention. Standardization 
occurred by dividing the number of patients vaccinated by the total number of eligible patients 
seen. 
Outcomes 
Data was collected from one internal medicine clinic, four family practice clinics, and  
five women’s health clinics at this FQHC. This includes 68 providers overall. The data was 
provided to the investigator de-identified for non-pregnant females ages 18-26 from the above 
clinics.  Post data collection ran from December 1st, 2017 to February 28th, 2018. Pre-
intervention included the time period from December 1st, 2016 to February 28th, 2017.  
 
Project Results 
          The overall results show an increase in HPV vaccination rates.  Pre-intervention, 190 HPV 
vaccines were given, and post-intervention 350 HPV vaccines were given. This result is not 
statistically significant, (M = -16.30,SD = 23.58); t(9)=- 2.19; p = 0.057 with a 95% CI. Total 
patients seen increased from 3137 to 3541 which is not statistically different (M = -40.40, SD = 
75.90); t(9)=- 1.68; p = 0.127. However, having two populations that are statistically similar with 
an increase in vaccination rates is a clinically significant finding. Standardizing the patients 
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yielded a percentage of individuals that received the vaccine before and after the intervention. 
Paired samples test reveal that there was an increase in percentage of those who received the 
HPV vaccine, but it is not statistically significant, (M = -.070 ,SD = .1068); t(9)=- 2.08; p = 
0.068.  
             Divided into specialty, all HPV vaccine rates increased and women’s health increased by 
the largest margin (See Appendix E). In internal medicine, 8 HPV vaccines were given pre-
intervention and 28 post-intervention. In family practice, 97 HPV vaccines were given pre-
intervention and 137 post-intervention. In women’s health, 85 HPV vaccines were given pre-
intervention and 187 post-intervention. All specialties saw similar patient visits standardizing the 
patients that received the vaccine before and after the intervention. 
Impact  
This project impacts providers, patients, the health system, and health policy. Providers  
were able to comply with national guidelines, maximize efficiency during busy appointments 
types, and use the BPA as a reminder for the HPV vaccine. The BPA provides a resource for 
providers to quickly check HPV vaccine status on a patient during busy appointments. Patients 
have an increase of awareness of HPV and the HPV vaccine, potential protection from the HPV 
and related urogenital cancers and warts, and added value to their visit. Education empowers 
patients to participate in their healthcare and raises satisfaction. The system benefits, as this is a 
sustainable EHR system change, can be utilized for other vaccines, and facilitates timeliness of 
the HPV vaccine series. The HPV BPA is a low maintenance system change and will only need 
to be updated if the national guidelines change regarding the HPV vaccine dosing timeline. 
Finally, health policy is impacted in that the HPV vaccine decreases new cases of HPV each 
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year, with it the cost burden of evaluation and treatment of HPV. The increase in HPV 
vaccination rates also aligns with the national health policy of Healthy People 2020 goal. 
Discussion 
               The HPV BPA alert was not present within the EHR prior to this system change at the 
project site. Following the completion of this project, the HPV BPA will remain in the EHR, 
making it a sustainable change. The low maintenance of the HPV BPA is ideal to be broadened 
to other health maintenance activities and other vaccines like the influenza vaccine. This project 
had similar findings to other literature. Clinical reminders for providers have been shown to 
increase in vaccination rates, which this project contributes to that database. The project also 
showed a positive correlation between a BPA and HPV vaccine uptake. Similar findings with 
other vaccinations and health maintenance tasks have been established (Fiks et al., 2013; Klatt & 
Hopp, 2012; Ledwich et al., 2009; Ruffin et al., 2015). Future research is needed to focus on the 
missed opportunities for HPV vaccination with a BPA in place. Rates of provider 
recommendation, refusal rates, BPA impact on completion of the HPV vaccine series, and the 
use of BPAs on other vaccines are also areas of future research. Future research could also look 
at the effectiveness of BPAs in the pediatric population. 
            The biggest strength to this project is after the implementation of a HPV BPA, the rates 
of HPV vaccination increased across multiple specialties that saw adult females ages 18-26.  
This shows that a HPV BPA replicated into another clinical site should show similar results no 
matter the specialty.  This is a sustainable, low maintenance intervention that can be used for a 
number of other vaccines.  Limitations of this project include the restrictions of the type of data 
that could be collected and challenges with the sensitivity of the alert to older versions of the 
vaccine and manually entered vaccines.  The most significant gap in the data was the inability to 
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capture missed opportunities; meaning while an increase in vaccination rates was demonstrated, 
there is not a way of knowing how many of those females were eligible for the vaccine or 
declined the vaccine. There was also no data on number of times the alert was utilized thus it was 
difficult to tell if the increase was due to providers using the alert or another variable. 
Conclusion 
While this project had significant limitations in both data collection and the technology  
used to capture vaccine history, it did increase provider awareness of previously low vaccination 
rates and the increase in vaccination rates was clinically significant. An increase in the HPV 
vaccine leads to protection of more individuals from the HPV virus, an increase in provider 
adherence to national guidelines, and provides a platform for BPAs to be utilized for other 
vaccines. 
 
 
 
 
 
 
 
 
 
 
 
 
HPV BPA ALERT 
 
16 
References 
American Congress of Obstetricians and Gynecologists (2015). Human papillomavirus 
            vaccination. Retrieved from http://www.acog.org/Resources-And- 
Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Human-
Papillomavirus-Vaccination 
Bartlett, J. A., & Peterson, J. A. (2011). The uptake of human papillomavirus (HPV) vaccine  
among adolescent females in the united states: A review of the literature. Journal of 
School Nursing (Sage Publications Inc.), 27(6), 434-446. 
Berenson, A. B., Rahman, M., Hirth, J. M., Rupp, R. E., & Sarpong, K. O. (2015). A brief  
educational intervention increases providers' human papillomavirus vaccine knowledge. 
Human Vaccines & Immunotherapeutics, 11(6), 1331-1336. 
doi:10.1080/21645515.2015.1022691 
Berkowitz, Z., Malone, M., Rodriguez, J., & Saraiya, M. (2015). Providers' beliefs about the  
effectiveness of the HPV vaccine in preventing cancer and their recommended age 
groups for vaccination: Findings from a provider survey, 2012. Preventive Medicine, 81, 
405-411. 
Bratic, J. S., Seyferth, E. R., & Bocchini, J. A. (2016). Update on barriers to human  
papillomavirus vaccination and effective strategies to promote vaccine acceptance. 
Current Opinion in Pediatrics, 28(3), 407-412. 
Centers for Disease Control and Prevention (2016a). Cervical cancer rates by state. Retrieved  
           from https://www.cdc.gov/cancer/cervical/statistics/state.htm 
Centers for Disease Control and Prevention (2016b). Gynecological cancers. Cervical cancer  
            statistics. Retrieved from https://www.cdc.gov/cancer/cervical/statistics/ 
HPV BPA ALERT 
 
17 
Centers for Disease Control and Prevention (2016c). Vaccine recommendations of the ACIP.  
            Retrieved from http://www.cdc.gov/vaccines/hcp/acip-recs/index.html 
Centers for Disease Control and Prevention (2016d). 2015 Sexually transmitted diseases  
             surveillance. Retrieved from https://www.cdc.gov/std/stats15/other.htm#hpv 
Centers for Disease Control and Prevention (2015). HPV and latino health. Retrieved  
from http://www.cdc.gov/features/hpv-latino/ 
Centers for Disease Control and Prevention (2015b) Human papilommavirus (HPV): Know the  
            facts. Retrieved from https://www.cdc.gov/hpv/hcp/know-facts.html 
Gilkey, M. B., Calo, W. A., Moss, J. L., Shah, P. D., Marciniak, M. W., & Brewer, N. T. (2016).  
Provider communication and HPV vaccination: The impact of recommendation quality. 
Vaccine, 34(9), 1187-1192. doi:10.1016/j.vaccine.2016.01.023 
Gilkey, M. B., & McRee, A. (2016). Provider communication about HPV vaccination: A  
            systematic review. Human Vaccines & Immunotherapeutics, 12(6), 1454- 1468.          
            doi:http://dx.doi.org.ezproxy1.lib.asu.edu/10.1080/21645515.2015.1129090 
Hofstetter, A. M., & Rosenthal, S. L. (2014). Factors impacting HPV vaccination: Lessons for  
health care professionals. Expert Review of Vaccines, 13(8), 1013-1026. 
doi:10.1586/14760584.2014.933076 
Fiks, A.G., Grundmeier, R. W., Mayne, S., Song, L.,Feemster, K., Karavite, D., Hughes, C.C.,  
Massey, J., Keren, R., Bell, L.M., Wasserman, R., & Localio. A.R. (2013). Effectiveness 
of Decision Support for Families, Clinicians, or Both on HPV Vaccine 
Receipt. Pediatrics, 131(6), 1114-24. 
Klatt, T., & Hopp, E. (2012). Effect of a best-practice alert on the rate of influenza vaccination of  
pregnant women. Obstetrics and Gynecology, 119(2 Pt 1), 301-5. 
HPV BPA ALERT 
 
18 
Ledwich, L., Harrington, T., Ayoub, W., Sartorius, J., & Newman, E. (2009). Improved  
influenza and pneumococcal vaccination in rheumatology patients taking 
immunosuppressants using       
        an electronic health record best practice alert. Arthritis Care & Research,61(11), 1505-     
        1510. 
Meites, E., Kempe, A., & Markowitz, L. E. (2016). Use of a 2-dose schedule for human  
papillomavirus vaccination - updated recommendations of the advisory committee on 
immunization practices. MMWR. Morbidity and Mortality Weekly Report, 65(49), 1405. 
National Vaccine Advisory Committee. (2016). Overcoming barriers to low HPV vaccine uptake 
 in the united states: Recommendations from the national vaccine advisory committee: 
Approved by the national vaccine advisory committee on June 9, 2015. Public Health 
Reports (Washington, D.C.: 1974), 131(1), 17-25. 
Nursing Theory. (2016). Health Promotion Model. Retrieved from http://www.nursing- 
 theory.org/theories-and-models/pender-health-promotion-model.php 
Office of Disease Prevention and Health Promotion (2017). Immunization and infectious  
diseases. Healthy people 2020. Retrieved from https://www.healthypeople.gov/2020/ 
topics-objectives/topic/immunization-and-infectious-diseases/objectives 
Petrosky, E., Bocchini, J., Joseph A, Hariri, S., Chesson, H., Curtis, C. R., Saraiya, M., Unger,  
E.R., Markowitz, L.E., Centers for Disease Control and Prevention (CDC). (2015). Use 
of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination 
recommendations of the advisory committee on immunization practices. MMWR. 
Morbidity and Mortality Weekly Report, 64(11), 300. 
Ruffin, M. T.,4th, Plegue, M. A., Rockwell, P. G., Young, A. P., Patel, D. A., & Yeazel, M. W.  
HPV BPA ALERT 
 
19 
 (2015). Impact of an electronic health record (EHR) reminder on human papillomavirus 
 (HPV) vaccine initiation and timely completion. Journal of the American Board of 
 Family Medicine : JABFM, 28(3), 324-333. doi:10.3122/jabfm.2015.03.140082 [doi] 
Rycroft-Malone, J., & Bucknall, T. (2010). Models and frameworks for implementing evidence- 
 based practice: Linking evidence to action. Chichester, West Sussex: Wiley-Blackwell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV BPA ALERT 
 
20 
Appendix A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV BPA ALERT 
 
21 
Appendix B 
Individual Characteristics 
and Experiences 
Behavior-Specific Cognitions 
and Affect 
Behavioral Outcomes 
Prior-Related Behavior: 
• Low provider HPV 
recommendation 
rates 
Personal Factors: 
• Busy appointment 
times 
• Forgetfulness 
• Different chief 
complaints 
Perceived benefits of action: 
• HPV vaccination 
• Cancer prevention 
Potential Barriers to Action: 
• Patient resistance 
• Lack of education 
• BPA not utilized 
Situational Influences 
• BPA in the EHR 
Health Promoting Behavior 
• Provider 
recommends 
vaccine 
• Patient receives 
vaccine 
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